JP2023086719A5 - - Google Patents
Info
- Publication number
- JP2023086719A5 JP2023086719A5 JP2022197331A JP2022197331A JP2023086719A5 JP 2023086719 A5 JP2023086719 A5 JP 2023086719A5 JP 2022197331 A JP2022197331 A JP 2022197331A JP 2022197331 A JP2022197331 A JP 2022197331A JP 2023086719 A5 JP2023086719 A5 JP 2023086719A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cdk4
- therapeutic agent
- abemaciclib
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288179P | 2021-12-10 | 2021-12-10 | |
| US63/288,179 | 2021-12-10 | ||
| US202263321218P | 2022-03-18 | 2022-03-18 | |
| US63/321,218 | 2022-03-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023086719A JP2023086719A (ja) | 2023-06-22 |
| JP2023086719A5 true JP2023086719A5 (enExample) | 2025-11-06 |
Family
ID=85157124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022197331A Pending JP2023086719A (ja) | 2021-12-10 | 2022-12-09 | Ｃｄｋ４及び６阻害剤で以前に治療された患者におけるホルモン受容体陽性でヒト上皮成長因子受容体２陰性の進行性又は転移性乳がんの治療のためのフルベストラントとのｃｄｋ４及び６阻害剤の併用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240398832A1 (enExample) |
| EP (1) | EP4444315A1 (enExample) |
| JP (1) | JP2023086719A (enExample) |
| KR (1) | KR20240118134A (enExample) |
| AU (1) | AU2022408062B2 (enExample) |
| CA (1) | CA3240454A1 (enExample) |
| IL (1) | IL313422A (enExample) |
| MX (1) | MX2024007015A (enExample) |
| TW (1) | TW202342044A (enExample) |
| WO (1) | WO2023107525A1 (enExample) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04005939A (es) | 2002-01-22 | 2005-01-25 | Warner Lambert Co | 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas. |
| AU2004255934B2 (en) | 2003-07-11 | 2010-02-25 | Warner-Lambert Company Llc | Isethionate salt of a selective CDK4 inhibitor |
| BRPI0716880A2 (pt) | 2006-09-08 | 2013-10-15 | Pfizer Prod Inc | Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| MX386473B (es) | 2013-02-21 | 2025-03-18 | Pfizer | Formas solidas de un inhibidor de cdk4/6 selectivo |
| AU2017235450A1 (en) * | 2016-03-15 | 2018-08-16 | Merrimack Pharmaceuticals, Inc. | Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody |
| EP3618820A1 (en) | 2017-05-02 | 2020-03-11 | Eli Lilly and Company | Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer |
| US11576919B2 (en) * | 2019-08-12 | 2023-02-14 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant |
-
2022
- 2022-12-07 WO PCT/US2022/052071 patent/WO2023107525A1/en not_active Ceased
- 2022-12-07 MX MX2024007015A patent/MX2024007015A/es unknown
- 2022-12-07 AU AU2022408062A patent/AU2022408062B2/en active Active
- 2022-12-07 EP EP22851077.2A patent/EP4444315A1/en active Pending
- 2022-12-07 IL IL313422A patent/IL313422A/en unknown
- 2022-12-07 CA CA3240454A patent/CA3240454A1/en active Pending
- 2022-12-07 US US18/717,475 patent/US20240398832A1/en active Pending
- 2022-12-07 KR KR1020247022368A patent/KR20240118134A/ko active Pending
- 2022-12-09 JP JP2022197331A patent/JP2023086719A/ja active Pending
- 2022-12-09 TW TW111147357A patent/TW202342044A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022022264A5 (enExample) | ||
| Marshall et al. | Amenorrhoea in anorexia nervosa: assessment and treatment with clomiphene citrate | |
| JP2023174661A5 (enExample) | ||
| JP2022509262A5 (enExample) | ||
| JP2019529581A5 (enExample) | ||
| JP2023522166A5 (enExample) | ||
| JP2019508476A5 (enExample) | ||
| JP2022544485A5 (enExample) | ||
| JP2005519893A5 (enExample) | ||
| KR100782638B1 (ko) | 에스트로겐 화합물 및 프로게스테론 화합물로 이루어진호르몬 조성물 | |
| JP2023175688A5 (enExample) | ||
| JP2024102045A5 (enExample) | ||
| JP2023549196A5 (enExample) | ||
| JP2003528919A5 (enExample) | ||
| JP2022543679A5 (enExample) | ||
| JP2023086719A5 (enExample) | ||
| JP2024506385A5 (enExample) | ||
| HUP0101005A2 (hu) | Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére | |
| JP2005530791A (ja) | 結合型エストロゲンとトリメゲストンの組み合わせを用いたホルモン補充療法 | |
| US6245812B1 (en) | Treatment of hot flashes (flushing) using leucine alone or in combination with other branched chain amino acids | |
| IL313422A (en) | CDK4 and 6 inhibitor in combination with FULVESTRANT for the treatment of advanced or metastatic breast cancer in patients with advanced or metastatic breast cancer before CDK 4 and 4 | |
| JP2004529924A5 (enExample) | ||
| JP2024506347A5 (enExample) | ||
| CA2472309A1 (en) | Multiple dose aromatase inhibitor for treating infertility | |
| JP2005530790A (ja) | 閉経後の障害を治療するためのトリメゲストンおよびエストロゲン |